<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7286522\results\search\tropicalVirus\results.xml">
  <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Tropical Diseases"/>
  <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
  <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Oncology :"/>
  <result pre="virus replication by interfering with viral protein synthesis Bortezomib inhibits" exact="CHIKV" post="KaurParveenConceptualizationData curationFormal analysisInvestigationMethodologyValidationVisualizationWriting – original draft1LelloLaura SandraInvestigation2UttAgeInvestigationMethodologyValidationVisualizationWriting – review"/>
  <result pre="medium, provided the original author and source are credited.pntd.0008336.pdf Abstract" exact="Chikungunya" post="virus (CHIKV) is an alphavirus that causes a febrile"/>
  <result pre="health threat, there are no approved therapeutics or prophylactics for" exact="CHIKV" post="infection. In this study, we explored the anti-CHIKV effects"/>
  <result pre="A panel of proteasome inhibitors with different functional groups reduced" exact="CHIKV" post="infectious titers in a dose-dependent manner. Bortezomib, which has"/>
  <result pre="activities of bortezomib were confirmed using different cellular models and" exact="CHIKV" post="strains. Time-of-addition and time-of-removal studies suggested that bortezomib inhibited"/>
  <result pre="CHIKV strains. Time-of-addition and time-of-removal studies suggested that bortezomib inhibited" exact="CHIKV" post="at an early, post-entry stage of replication. In western"/>
  <result pre="qRT-PCR data revealed increased levels of both positive- and negative-sense" exact="CHIKV" post="RNA at late stages of infection. It is likely"/>
  <result pre="being a contributing factor. Proteasome inhibitors like bortezomib likely disrupt" exact="CHIKV" post="replication through a variety of complex mechanisms and may"/>
  <result pre="and may display a potential for use as therapeutics against" exact="CHIKV" post="infection. They also represent valuable tools for studies of"/>
  <result pre="CHIKV infection. They also represent valuable tools for studies of" exact="CHIKV" post="molecular biology and virus-host interactions. Author summary Chikungunya virus"/>
  <result pre="studies of CHIKV molecular biology and virus-host interactions. Author summary" exact="Chikungunya" post="virus (CHIKV) is a mosquito-transmitted virus that causes an"/>
  <result pre="that causes an illness with debilitating muscle and joint pain." exact="CHIKV" post="has infected millions in a continued wave of outbreaks"/>
  <result pre="Despite this, there are no approved antivirals or vaccines against" exact="CHIKV" post="infection. In this study, we explored the inhibitory effects"/>
  <result pre="CHIKV. A panel of proteasome inhibitors was found to reduce" exact="CHIKV" post="titres in CHIKV-infected cells. We selected bortezomib, an FDA-approved"/>
  <result pre="the anti-CHIKV effects of bortezomib using different cell lines and" exact="CHIKV" post="strains. We found that bortezomib resulted in a major"/>
  <result pre="that bortezomib resulted in a major decrease in levels of" exact="CHIKV" post="structural proteins, which are involved in formation of progeny"/>
  <result pre="also prominently increased synthesis of viral replicase components and increased" exact="CHIKV" post="RNA synthesis. We propose that proteasome inhibitors like bortezomib"/>
  <result pre="propose that proteasome inhibitors like bortezomib are likely to inhibit" exact="CHIKV" post="through various mechanisms that ultimately lead to a decrease"/>
  <result pre="inhibitors display a potential for further development as antivirals against" exact="CHIKV" post="infection and may be useful tools to study CHIKV"/>
  <result pre="against CHIKV infection and may be useful tools to study" exact="CHIKV" post="molecular biology and virus-host interactions. Funding This study was"/>
  <result pre="are within the manuscript and its Supporting Information files. Introduction" exact="Chikungunya" post="virus (CHIKV) is a mosquito-borne virus that has re-emerged"/>
  <result pre="major public health threat in the last decade [1, 2]." exact="CHIKV" post="infection results in a febrile illness accompanied by debilitating"/>
  <result pre="5, 6]. While historically confined to Asia and sub-Saharan Africa," exact="CHIKV" post="outbreaks have recently also been reported in non-endemic areas,"/>
  <result pre="millions [2, 7–9]. Factors contributing to the continued waves of" exact="CHIKV" post="epidemics worldwide include increased global travel and rising global"/>
  <result pre="CHIKV, there are currently no licensed therapeutics or prophylactics against" exact="CHIKV" post="infection. There remains an urgent need for the discovery"/>
  <result pre="an urgent need for the discovery of novel antivirals against" exact="CHIKV" post="infection, accompanied by an improved understanding of CHIKV replication"/>
  <result pre="antivirals against CHIKV infection, accompanied by an improved understanding of" exact="CHIKV" post="replication and pathogenesis. CHIKV belongs to the genus Alphavirus"/>
  <result pre="accompanied by an improved understanding of CHIKV replication and pathogenesis." exact="CHIKV" post="belongs to the genus Alphavirus in the Togaviridae family"/>
  <result pre="belongs to the genus Alphavirus in the Togaviridae family [12]." exact="CHIKV" post="is part of the Old World alphaviruses, which also"/>
  <result pre="viruses, Semliki Forest virus (SFV) and Sindbis virus (SINV) [13]." exact="Chikungunya" post="virions are enveloped, with a positive-sense RNA genome enclosed"/>
  <result pre="positive-sense RNA genome enclosed within a nucleocapsid core [12]. The" exact="CHIKV" post="genome is approximately 11.8 kb long and contains two"/>
  <result pre="14]. Glycoprotein spikes consisting of E1 and E2 on the" exact="CHIKV" post="envelope mediate virion binding and entry into host cells"/>
  <result pre="viral replicase [17]. The viral replicase generates the full-length negative-sense" exact="CHIKV" post="RNA, which serves as a template for the transcription"/>
  <result pre="full-length positive-sense genomic (G), as well as the subgenomic (SG)" exact="CHIKV" post="RNAs [18]. This is followed by translation of the"/>
  <result pre="the SG RNA [13]. In the later stages of the" exact="CHIKV" post="replication cycle, the nucleocapsid core assembles in the cytoplasm"/>
  <result pre="although results differed between studies [34, 35]. For instance, upon" exact="CHIKV" post="infection, PSMA6 (proteasome subunit alpha type-6) was reported to"/>
  <result pre="was found to interfere with a post-entry step in the" exact="CHIKV" post="replication cycle. Treatment with bortezomib also resulted in a"/>
  <result pre="structural protein expression. Western blot analysis showed elevated levels of" exact="CHIKV" post="nsP4 from early time-points, suggesting the possibility that the"/>
  <result pre="CHIKV nsP4 from early time-points, suggesting the possibility that the" exact="CHIKV" post="nsP4 is degraded by the proteasome, similar to the"/>
  <result pre="levels was also observed. Levels of both positive-sense and negative-sense" exact="CHIKV" post="RNA were elevated at later time-points post-infection. This study"/>
  <result pre="study shows that proteasome inhibitors affect different processes involved in" exact="CHIKV" post="replication and may serve as potential antivirals against CHIKV."/>
  <result pre="against CHIKV. Further work into their clinical therapeutic use during" exact="CHIKV" post="infection is warranted. Results Proteasome inhibitors suppress CHIKV infection"/>
  <result pre="use during CHIKV infection is warranted. Results Proteasome inhibitors suppress" exact="CHIKV" post="infection In order to explore the anti-CHIKV effects of"/>
  <result pre="with 0.1 μM bortezomib onwards resulted in significant inhibition of" exact="CHIKV" post="infectious titer. A maximal 98.5% (2.2 log10 units) inhibition"/>
  <result pre="bortezomib could affect the cells in a way that hindered" exact="CHIKV" post="attachment or entry. The inhibitory trend was not observed"/>
  <result pre="the replication cycle. Fig 1 Effects of bortezomib treatment on" exact="CHIKV" post="infection in BHK21 cells. (A) BHK21 cells were infected"/>
  <result pre="CHIKV-122508 and treated with indicated concentrations of bortezomib for 24h." exact="CHIKV" post="titers are presented in the bar graphs corresponding to"/>
  <result pre="order to confirm the antiviral effects of proteasome inhibition on" exact="CHIKV" post="infection, a panel of proteasome inhibitors from compound classes"/>
  <result pre="cells. As shown in Fig 2, most proteasome inhibitors inhibited" exact="CHIKV" post="replication at concentrations that were minimally cytotoxic, indicating that"/>
  <result pre="were minimally cytotoxic, indicating that proteasomal inhibition is detrimental to" exact="CHIKV" post="infection. The inhibition in CHIKV titers observed for MG132"/>
  <result pre="proteasomal inhibition is detrimental to CHIKV infection. The inhibition in" exact="CHIKV" post="titers observed for MG132 (Fig 2A) and lactacystin (Fig"/>
  <result pre="resulted in decreasing cell viabilities, suggesting that the inhibition in" exact="CHIKV" post="titers observed for these two compounds may be a"/>
  <result pre="suggested that the proteasome may play a pro-viral role in" exact="CHIKV" post="replication. It is likely that the varying mechanisms of"/>
  <result pre="by different proteasomal inhibitors influenced the magnitude of inhibition of" exact="CHIKV" post="infection. Fig 2 Effects of proteasome inhibitors on CHIKV"/>
  <result pre="of CHIKV infection. Fig 2 Effects of proteasome inhibitors on" exact="CHIKV" post="infection in BHK21 cells. BHK21 cells were infected with"/>
  <result pre="harvested for plaque assays at 24 hpi. Percentage inhibition of" exact="CHIKV" post="titers by proteasome inhibitors are presented in the bar"/>
  <result pre="samples to vehicle control). Inhibitory effects of bortezomib across different" exact="CHIKV" post="strains and cell lines In order to confirm that"/>
  <result pre="the inhibitory effects observed were not due to cell-line- or" exact="CHIKV" post="strain-dependent effects, bortezomib was tested in two additional cell"/>
  <result pre="treatment resulted in a dose-dependent reduction of titer for both" exact="CHIKV" post="strains (Fig 3A). A maximal inhibition of 1.8 log10"/>
  <result pre="primary human skeletal myoblasts (HSMM), an in vivo target of" exact="CHIKV" post="infection [40, 41]. In agreement with results from BHK21"/>
  <result pre="41]. In agreement with results from BHK21 and HeLa cells," exact="CHIKV" post="replication in HSMM cells was inhibited in a dose-dependent"/>
  <result pre="as it is a human cell line in which high" exact="CHIKV" post="titers of &amp;gt;106 PFU/ml were obtained. Fig 3 Inhibitory"/>
  <result pre="were obtained. Fig 3 Inhibitory effects of bortezomib on different" exact="CHIKV" post="strains and cell lines. (A) HeLa cells were infected"/>
  <result pre="with CHIKV-122508 or CHIKV-0708 and post-treated with bortezomib for 24h." exact="CHIKV" post="titers are presented in the bar graphs corresponding to"/>
  <result pre="were infected with CHIKV-122508 and post-treated with bortezomib for 24h." exact="CHIKV" post="titers are presented in the bar graphs corresponding to"/>
  <result pre="performed in HeLa cells to identify the window in the" exact="CHIKV" post="replication cycle where bortezomib exerts its effects. As displayed"/>
  <result pre="hpi. Dotted lines represent the duration of bortezomib treatment. (B)" exact="CHIKV" post="titers from time-of-addition and time-of-removal assays. Error bars represent"/>
  <result pre="protein levels We next evaluated the possibility that bortezomib affects" exact="CHIKV" post="RNA synthesis and/or viral RNA translation events. To investigate"/>
  <result pre="translation events. To investigate this further, the levels of various" exact="CHIKV" post="proteins were measured at different time-points post-infection in HeLa"/>
  <result pre="decrease of about 50 to 80% in levels of the" exact="CHIKV" post="structural proteins, E2, E1 and capsid, from 6 hpi"/>
  <result pre="at 6 hpi (Fig 6). Fig 5 Time-point studies of" exact="CHIKV" post="protein levels upon bortezomib treatment. HeLa cells were infected"/>
  <result pre="samples were harvested at different time-points post-infection and probed for" exact="CHIKV" post="proteins. (A) Western blot images are representative of two"/>
  <result pre="inhibitor-treated samples to vehicle control at each time-point for each" exact="CHIKV" post="protein). Fig 6 Dose-dependent studies of CHIKV protein levels"/>
  <result pre="time-point for each CHIKV protein). Fig 6 Dose-dependent studies of" exact="CHIKV" post="protein levels upon bortezomib treatment at 6 hpi. HeLa"/>
  <result pre="Protein samples were harvested at 6 hpi and probed for" exact="CHIKV" post="proteins. (A) Western blot images are representative of three"/>
  <result pre="Dunnett’s post-test comparing bortezomib-treated samples to vehicle control for each" exact="CHIKV" post="protein). Unlike the consistent and significant reductions observed for"/>
  <result pre="degradation, which may be counteracted by the reduced spreading of" exact="CHIKV" post="in the monolayer as a result of diminished virion"/>
  <result pre="the same treatment concentrations that resulted in reduction of infectious" exact="CHIKV" post="titers for CHIKV-122508 in HeLa cells (Fig 3A). However,"/>
  <result pre="in nsP4 levels upon proteasome inhibition may suggest that the" exact="CHIKV" post="nsP4 is degraded by the proteasome, similar to the"/>
  <result pre="nsP4 of SFV and SINV [30, 31, 42]. Indeed, the" exact="CHIKV" post="nsP4 also contains a conserved destabilizing N-terminal Tyr residue"/>
  <result pre="N-terminal Tyr residue [12]. To identify potential ubiquitination sites in" exact="CHIKV" post="proteins, we ran the protein sequences of all CHIKV"/>
  <result pre="in CHIKV proteins, we ran the protein sequences of all" exact="CHIKV" post="proteins in UbPred, a random forest-based predictor of protein"/>
  <result pre="a random forest-based predictor of protein ubiquitination sites [43]. The" exact="CHIKV" post="nsP4 protein showed the highest number of predicted ubiquitination"/>
  <result pre="of medium or high, further supporting the possibility that the" exact="CHIKV" post="nsp4 is a substrate for the proteasome. It is"/>
  <result pre="to 8 hpi. To determine whether the bortezomib-induced changes in" exact="CHIKV" post="protein levels extended to other proteasome inhibitors as well,"/>
  <result pre="pathways, despite differences in functional groups. Fig 7 Changes in" exact="CHIKV" post="protein levels upon treatment with various proteasome inhibitors at"/>
  <result pre="Protein samples were harvested at 6 hpi and probed for" exact="CHIKV" post="proteins. (A) Western blot images are representative of two"/>
  <result pre="t-test comparing proteasome inhibitor-treated samples to vehicle control for each" exact="CHIKV" post="protein). Alphavirus infections are known to induce translational shut-off"/>
  <result pre="to be inhibited by nsP4, possibly to allow accumulation of" exact="CHIKV" post="RNA transcripts for subsequent translation [47]. To understand the"/>
  <result pre="t-test comparing proteasome inhibitor-treated samples to vehicle control for each" exact="CHIKV" post="protein). Bortezomib treatment increases in CHIKV RNA levels Given"/>
  <result pre="vehicle control for each CHIKV protein). Bortezomib treatment increases in" exact="CHIKV" post="RNA levels Given the alterations to CHIKV ns protein"/>
  <result pre="treatment increases in CHIKV RNA levels Given the alterations to" exact="CHIKV" post="ns protein levels, we also evaluated the effects of"/>
  <result pre="protein levels, we also evaluated the effects of bortezomib on" exact="CHIKV" post="RNA levels. Bortezomib treatment increased total CHIKV RNA levels"/>
  <result pre="of bortezomib on CHIKV RNA levels. Bortezomib treatment increased total" exact="CHIKV" post="RNA levels from 12 hpi onwards (Fig 9A), likely"/>
  <result pre="This increasing trend was observed for both positive-sense and negative-sense" exact="CHIKV" post="RNA at 12 hpi and 24 hpi (Fig 9B),"/>
  <result pre="suggesting that bortezomib induces similar effects on replication of both" exact="CHIKV" post="strands. Nonetheless, with no negative effect on CHIKV RNA"/>
  <result pre="of both CHIKV strands. Nonetheless, with no negative effect on" exact="CHIKV" post="RNA synthesis, it is clear that the major direct"/>
  <result pre="effect would require more extensive study. Fig 9 Changes in" exact="CHIKV" post="RNA levels upon bortezomib treatment. HeLa cells were infected"/>
  <result pre="of total RNA from infected cells. Levels of (A) total" exact="CHIKV" post="RNA or (B) strand-specific CHIKV RNA were detected by"/>
  <result pre="cells. Levels of (A) total CHIKV RNA or (B) strand-specific" exact="CHIKV" post="RNA were detected by qRT-PCR. Actin mRNA was used"/>
  <result pre="for normalization. The bar graph shows the fold change of" exact="CHIKV" post="RNA in bortezomib-treated samples compared to untreated samples. Fold"/>
  <result pre="study, we explored the inhibitory effects of proteasome inhibitors on" exact="CHIKV" post="replication, with some investigation into their mechanism of antiviral"/>
  <result pre="proteasome inhibitors from different compound classes were found to reduce" exact="CHIKV" post="infectious titers in a dose-dependent manner. Bortezomib, which has"/>
  <result pre="multiple myeloma and mantle cell lymphoma, showed dose-dependent reductions of" exact="CHIKV" post="titers in several cell lines (BHK21, HeLa and HSMM)."/>
  <result pre="several cell lines (BHK21, HeLa and HSMM). Bortezomib-mediated suppression of" exact="CHIKV" post="titers was found to occur at an early, post-entry"/>
  <result pre="prominent reductions (50 to 80%) in the levels of structural" exact="CHIKV" post="proteins (E2, E1 and capsid) in time-course studies as"/>
  <result pre="proteasome inhibitors with different functional groups. Finally, an increase in" exact="CHIKV" post="RNA levels was observed from 12 hpi onwards. This"/>
  <result pre="onwards. This increase was observed for both positive- and negative-sense" exact="CHIKV" post="RNA. The major direct antiviral effect of bortezomib is"/>
  <result pre="of cellular proteins and viral host factors, which may affect" exact="CHIKV" post="replication in different ways. In previous studies, the antiviral"/>
  <result pre="increase in nsP4 levels upon bortezomib treatment suggests that the" exact="CHIKV" post="nsP4, like that of SFV and SINV, is degraded"/>
  <result pre="A similar explanation can be made for the fact that" exact="CHIKV" post="RNA levels were observed to be elevated only at"/>
  <result pre="SG RNA may explain the different effects of bortezomib on" exact="CHIKV" post="ns and structural proteins. A similar phenomenon has been"/>
  <result pre="machinery, the stabilization of host and viral factors involved in" exact="CHIKV" post="replication may have also contributed to the antiviral effects"/>
  <result pre="9 (DHX9) has recently been reported to be recruited to" exact="CHIKV" post="replication complexes and may function as a switch regulating"/>
  <result pre="Importantly, DHX9 was shown to be required for translation of" exact="CHIKV" post="ns proteins during the early stages of replication while"/>
  <result pre="the proteasome [54]. While this has not been reported for" exact="CHIKV" post="nsP3, our data hints at a similar possibility. In"/>
  <result pre="In dose-dependent studies, treatment with 0.025 μM of bortezomib caused" exact="CHIKV" post="nsP3 levels to increase by about 30% above the"/>
  <result pre="that proteasome inhibitors apart from bortezomib caused similar changes to" exact="CHIKV" post="proteins, suggesting a common antiviral mechanism across proteasome inhibitors"/>
  <result pre="into the potential for these compounds to be used as" exact="CHIKV" post="antivirals is warranted. A limitation of bortezomib is its"/>
  <result pre="is six weeks long [37, 59, 63, 64]. However, for" exact="CHIKV" post="infection, treatment schedules are not expected to last as"/>
  <result pre="proteasome inhibitors with various functional groups are able to inhibit" exact="CHIKV" post="and cause similar changes to viral proteins. This indicates"/>
  <result pre="that in vivo evaluation of proteasome inhibitors for treatment of" exact="CHIKV" post="should not be limited to bortezomib. Rather, the use"/>
  <result pre="of bortezomib and other proteasome inhibitors in the context of" exact="CHIKV" post="infection. Extensive optimisations of the modified proteasome inhibitor structure,"/>
  <result pre="at 28°C without humidification. This study used two strains of" exact="CHIKV" post="East/Central/South African (ECSA) genotype: CHIKV-122508 (SGEHICHID122508, Accession No.: FJ445502.2)"/>
  <result pre="was propagated in BHK21 cells. Screening of proteasome inhibitors against" exact="CHIKV" post="Proteasome inhibitors were screened in post-treatment assays. BHK21 cells"/>
  <result pre="incubated overnight. HeLa monolayers were infected with different strains of" exact="CHIKV" post="at 10 for 1.5h at 37°C and washed twice"/>
  <result pre="at 48 hpi for titration via plaque assays. Studies on" exact="CHIKV" post="protein levels HeLa cells were seeded onto 6-well plates"/>
  <result pre="the accompanying LI-COR Image Studio programme. Measurement of changes in" exact="CHIKV" post="RNA levels upon bortezomib treatment HeLa cells were seeded"/>
  <result pre="ng of RNA. Primers targeting the capsid gene in the" exact="CHIKV" post="genome were used (forward primer: 5’-GCGGTACCCCAACAGAAG-3’; reverse primer: 5’-GGTTTCTTTTTAGGTGGCTG-3’)."/>
  <result pre="for additional data file. S2 Table Predicted ubiquitination sites within" exact="CHIKV" post="protein sequences. Ubiquitination sites were predicted using UbPred. Only"/>
  <result pre="64-year history. Int J Infect Dis. 2017;58:69–76. 10.1016/j.ijid.2017.03.00628288924 3SilvaLA, DermodyTS." exact="Chikungunya" post="virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies."/>
  <result pre="intervention strategies. J Clin Invest. 2017;127(3):737–49. 10.1172/JCI8441728248203 4StaplesJE, BreimanRF, PowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
  <result pre="Phylogenetic Study Provides New Insights on the Global Expansion of" exact="Chikungunya" post="Virus. J Virol. 2016;90(23):10600–11. 10.1128/JVI.01166-1627654297 10JohanssonMA, PowersAM, PesikN, CohenNJ,"/>
  <result pre="KuadkitkanA, JaimipukT, UbolS, PulmanausahakulR, et al.Identification of prohibitin as a" exact="Chikungunya" post="virus receptor protein. J Med Virol. 2012;84(11):1757–70. 10.1002/jmv.2340322997079 17LemmJA,"/>
  <result pre="chaperone, Nucleophosmin among the common set of proteins modulated in" exact="Chikungunya" post="virus infection. J Proteomics. 2015;120:126–41. 10.1016/j.jprot.2015.03.00725782748 36KarpeYA, PingaleKD, KanadeGD."/>
  <result pre="PingaleKD, KanadeGD. Activities of proteasome and m-calpain are essential for" exact="Chikungunya" post="virus replication. Virus Genes. 2016;52(5):716–21. 10.1007/s11262-016-1355-527206501 37HoySM. Subcutaneous bortezomib:"/>
  <result pre="of a Novel Primary Human Skeletal Myoblast Cellular Model for" exact="Chikungunya" post="Virus Infection and Pathogenesis.Sci Rep.2016;6:2140610.1038/srep2140626892458 41OzdenS, Lucas-HouraniM, CeccaldiPE, BasakA,"/>
  <result pre="Rep.2016;6:2140610.1038/srep2140626892458 41OzdenS, Lucas-HouraniM, CeccaldiPE, BasakA, ValentineM, BenjannetS, et al.Inhibition of" exact="Chikungunya" post="virus infection in cultured human muscle cells by furin"/>
  <result pre="Cells.Viruses. 2018;10(2). 47RathoreAP, NgML, VasudevanSG. Differential unfolded protein response during" exact="Chikungunya" post="and Sindbis virus infection: CHIKV nsP4 suppresses eIF2alpha phosphorylation.Virol"/>
  <result pre="Differential unfolded protein response during Chikungunya and Sindbis virus infection:" exact="CHIKV" post="nsP4 suppresses eIF2alpha phosphorylation.Virol J.2013;10:3610.1186/1743-422X-10-3623356742 48KeckF, AmayaM, Kehn-HallK, RobertsB,"/>
  <result pre="10.1007/s12250-019-00162-931637631 50ChoyMM, ZhangSL, CostaVV, TanHC, HorrevortsS, OoiEE. Proteasome Inhibition Suppresses" exact="Dengue" post="Virus Egress in Antibody Dependent Infection.PLoS Negl Trop Dis.2015;9(11):e000405810.1371/journal.pntd.000405826565697"/>
  <result pre="HersiD, et al.The Host DHX9 DExH-Box Helicase Is Recruited to" exact="Chikungunya" post="Virus Replication Complexes for Optimal Genomic RNA Translation. J"/>
  <result pre="Soc. 2011;133(4):698–700. 10.1021/ja109377p21186803 67KaurP, LeeRC, ChuJJ. Infectious Viral Quantification of" exact="Chikungunya" post="Virus-Virus Plaque Assay.Methods Mol Biol. 2016;1426:93–103. 10.1007/978-1-4939-3618-2_927233264 68BroeckelR, SarkarS,"/>
 </snippets>
</snippetsTree>
